Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in the UK

被引：0
|
作者：
Aballea, S.
Chancellor, J. V. M.
Raikou, M.
Drummond, M. F.
Jourdan, S.
Carita, P.
Bridgewater, J.
Boler, A.
机构：
[1] Innovus Res UK Ltd, High Wycombe, Bucks, England
[2] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England
[3] London Sch Econ, London, England
[4] Sanofi Aventis R&D, Global Hlth Outcomes, Bagneux, France
[5] UCL Royal Free & Univ Coll, Sch Med, London, England
[6] Heron Evidence Dev, Letchworth Garden City, England
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：178 / 178
页数：1
相关论文
共 50 条
  • [31] The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation
    Pandor, A.
    Eggington, S.
    Paisley, S.
    Tappenden, P.
    Sutcliffe, P.
    HEALTH TECHNOLOGY ASSESSMENT, 2006, 10 (41) : 1 - +
  • [32] Final safety findings from a randomized phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.
    Schmoll, H. J.
    Tabernero, J.
    Nowacki, M.
    Maroun, J.
    Price, T.
    Lim, R.
    Van Cutsem, E.
    De Braud, F.
    Haller, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 163S - 163S
  • [33] Survival after adjuvant 5-FU treatment for stage III colon cancer: Possible role of mismatch repair (MMR) gene defect
    De Vos, WH
    Meulebeld, HJ
    Kleibeuker, JH
    Nagengast, FM
    Menko, FH
    Griffioen, G
    Cats, A
    Morreau, H
    Gelderblom, H
    Vasen, HFA
    GASTROENTEROLOGY, 2003, 124 (04) : A550 - A551
  • [34] 5-year overall survival update from the X-ACT trial of capecitabine vs. 5-FU/LV as adjuvant treatment for stage III colon cancer - Abstracts
    Twelves, C.
    Scheithauer, W.
    McKendrick, J.
    Nowacki, M.
    Seitz, J.
    Van Haze, G.
    Wong, A.
    Diaz-Rubio, E.
    Cassidy, J.
    EJC SUPPLEMENTS, 2007, 5 (06): : 1 - 1
  • [35] Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).
    Schmoll, Hans-Joachim
    Tabernero, Josep
    Maroun, Jean Alfred
    De Braud, Filippo G.
    Price, Timothy Jay
    Van Cutsem, Eric
    Hill, Mark
    Hoersch, Silke
    Rittweger, Karen
    Haller, Daniel G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [36] Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study
    Shibahara, Hidetoshi
    Shiroiwa, Takeru
    Ishiguro, Megumi
    Nakamura, Masato
    Hasegawa, Junichi
    Yamaguchi, Shigeki
    Masuda, Yuriko
    Sakamoto, Junichi
    Tomita, Naohiro
    Fukuda, Takashi
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2022, 23 (07): : 1159 - 1171
  • [37] Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study
    Hidetoshi Shibahara
    Takeru Shiroiwa
    Megumi Ishiguro
    Masato Nakamura
    Junichi Hasegawa
    Shigeki Yamaguchi
    Yuriko Masuda
    Junichi Sakamoto
    Naohiro Tomita
    Takashi Fukuda
    The European Journal of Health Economics, 2022, 23 : 1159 - 1171
  • [38] SAFETY AND ACTIVITY OF AN ALTERNATINIG REGIMEN OF IRINOTECAN/5-FU/LV AND OXALIPLATIN/5-FU/LV (FAFOXIRI) IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER (MCC)
    Amoroso, Vito
    Ferrari, Vittorio
    Valcamonico, Francesca
    Vassalli, Lucia
    Simoncini, Edda
    Grisanti, Salvatore
    Marpicati, Patrizia
    Rangoni, Giovanni
    Marini, Giovanni
    ANNALS OF ONCOLOGY, 2004, 15 : 62 - 63
  • [39] THE ADJUVANT TREATMENT OF STAGE 3 COLON CANCER (ACC): AN INDIRECT COST-MINIMISATION AND POPULATION NET HEALTH BENEFIT ANALYSIS OF CAPECITABINE plus OXALIPLATIN (XELOX) VS. IV 5-FU + FA + OXALIPLATIN (FOLFOX)
    Garside, J.
    McNamara, S.
    Millar, D.
    VALUE IN HEALTH, 2011, 14 (07) : A453 - A453
  • [40] Cost-Effectiveness of Adjuvant FOLFOX Therapy for Stage III Colon Cancer in Japan Based on the MOSAIC Trial
    Shiroiwa, Takeru
    Takeuchi, Toshihiro
    Fukuda, Takashi
    Shimozuma, Kojiro
    Ohashi, Yasuo
    VALUE IN HEALTH, 2012, 15 (02) : 255 - 260
12345